Page 39 - GTM-1-2

Global Translational Medicine Proteomic analysis of heart in metabolic cardiomyopathy

Fund of Affiliated Hospital of Southwest Medical University contribution of the Heart Failure Association (HFA) of the
(No. 18014). ESC. Eur Heart J, 37: 2129–2200.
https://doi.org/10.1093/eurheartj/ehw128
Conflict of interest
6. Isfort M, Stevens SC, Schaffer S, et al., 2014, Metabolic
The authors declare that there are no conflicts of interest dysfunction in dia betic cardiomyopathy. Heart Fail Rev,
regarding the publication of this paper. 19: 35–48.

Author contributions https://doi.org/10.1007/s10741-013-9377-8
7. Seferovic PM, Paulus WJ, 2015, Clinical diabetic
Conceptualization: Wei Huang cardiomyopathy: A two-faced disease with restrictive and
Investigation: Zongzhe Jiang, Mingyang Pang dilated phenotypes. Eur Heart J, 36: 1718–1727, 1727a–1727c.
Formal analysis: Wei Huang
Writing-original draft: Zongzhe Jiang, Mingyang Pang https://doi.org/10.1093/eurheartj/ehv134
Writing-review and editing: Huang Wei 8. Authors/Task Force Members, Ryden L, Grant PJ, et al., 2013,
ESC guidelines on diabetes, prediabetes, and cardiovascular
Ethics approval and consent to participate diseases developed in collaboration with the EASD: the task
force on diabetes, pre-diabetes, and cardiovascular diseases
Animal experiments were approved by the Institutional of the European Society of Cardiology (ESC) and developed
Animals Ethics Committees of Southwest Medical in collaboration with the European association for the study
University (Approval No. 20220225-014). Consent to of Diabetes (EASD). Eur Heart J, 34: 3035–3087.
participate is not applicable.
https://doi.org/10.1093/eurheartj/eht108
Consent for publication 9. Schulze PC, Drosatos K, Goldberg IJ, 2016, Lipid use and

Not applicable. misuse by the heart. Circ Res, 118: 1736–1751.
https://doi.org/10.1161/CIRCRESAHA.116.306842
Availability of data
10. Gibbs EM, Stock JL, McCoid SC, et al., 1995, Glycemic
The datasets used and analyzed in present study can be improvement in diabetic db/db mice by overexpression of
obtained from the corresponding author on reasonable the human insulinregulatable glucose transporter (GLUT4).
request. J Clin Invest, 95: 1512–1218.
https://doi.org/10.1172/JCI117823
References
11. Niture SK, Khatri R, Jaiswal AK, 2014, Regulation of Nrf2-an
1. Ogurtsova K, Da Rocha Fernandes JD, Huang Y, et al., 2017, IDF update. Free Radic Biol Med, 66: 36–44.
diabetes atlas: global estimates for the prevalence of diabetes for
2015 and 2040. Diabetes Res. Clin. Pract, 128: 40–50. https://doi.org/10.1016/j.freeradbiomed.2013.02.008
12. Tan Y, Ichikawa T, Li J, et al., 2011, Diabetic downregulation
https://doi.org/10.1016/j.diabres.2017.03.024
of Nrf2 activity via ERK contributes to oxidative stress-
2. Nishida K, Otsu K, 2017, Inflammation and metabolic induced insulin resistance in cardiac cells in vitro and in
cardiomyopathy. Cardiovasc Res, 113: 389–398. vivo. Diabetes, 60: 625–633.
https://doi.org/10.1093/cvr/cvx012 https://doi.org/10.2337/db10-1164
3. Maack C, Murphy E, 2017, Metabolic cardiomyopathies— 13. Jia G, DeMarco VG, Sowers JR, 2016, Insulin resistance and
fighting the next epidemic. Cardiovasc Res, 113: 367–369. hyperinsulinaemia in diabetic cardiomyopathy. Nat Rev
https://doi.org/10.1093/cvr/cvx022 Endocrinol, 12: 144–53.
4. Obokata M, Reddy YNV, Pislaru SV, et al., 2017, Evidence https://doi.org/10.1038/nrendo.2015.216
supporting the existence of a distinct obese phenotype of 14. Wang Y, Zhou S, Sun W, et al., 2014, Inhibition of JNK by novel
heart failure with preserved ejection fraction., Circulation, curcumin analog C66 prevents diabetic cardiomyopathy
136: 6–19. with a preservation of cardiac metallothionein expression.
Am J Physiol Endocrinol Metab, 306: E1239–E1247.
https://doi.org/10.1161/CIRCULATIONAHA.116.026807
https://doi.org/10.1152/ajpendo.00629.2013
5. Ponikowski P, Voors AA, Anker SD, et al., 2016, 2016 ESC
guidelines for the diagnosis and treatment of acute and 15. Winzell MS, Ahren B, 2004, The high-fat diet-fed mouse:
chronic heart failure: the task force for the diagnosis and A model for studying mecha-nisms and treatment of
treatment of acute and chronic heart failure of the European impaired glucose tolerance and Type 2 diabetes. Diabetes,
Society of Cardiology (ESC). Developed with the special 53: S215–S219.

Volume 1 Issue 2 (2022) 9 https://doi.org/10.36922/gtm.v1i2.137